The drug maker said it is in the midst of finalising the protocol to begin the trials on children and adolescents which will have two cohorts one for 12-18 years and 2-12 years age groups. “The dosing requirement is likely to be different for two cohorts,” said Deepak Sapra, CEO of API & Services, Dr Reddy’s, to media.
